Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease [Image: see text]

OBJECTIVES: Depression and antidepressant use, especially selective serotonin reuptake inhibitors (SSRIs), are common in Parkinson disease (PD). The objective of this clinical trial was to assess the efficacy of atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), for the treatment of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A.D., Duda, J.E., Hurtig, H.I., Colcher, A., Horn, S.S., Nazem, S., Ten Have, T.R., Stern, M.B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Academy of Neurology 2010
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2918470/
https://ncbi.nlm.nih.gov/pubmed/20679638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181ebdd79
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados